Medicine guide
Aucatzyl
- Prescription status not stated
- Cancer treatments and immune-system medicines
- Active substance
- Obecabtagene autoleucel
- Made by
- Autolus GmbH
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Aucatzyl is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory (r/r) B cell precursor acute lymphoblastic leukaemia (B ALL).
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Autolus GmbH |
|---|---|
| Active substance | Obecabtagene autoleucel |
| Used in | Cancer treatments and immune-system medicines |
| Classification | L01XL · Cancer treatments and immune-system medicines |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2025-07-17 |
| Last updated by the regulator | 2025-08-19 |
| EMA product number | EMEA/H/C/005907 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).